Hims vs Noom: Prescriber-First and App-First Compared

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This review is editorially independent. PlexusDx holds no commercial relationship with Hims or Noom, earns nothing from either brand, and uses no affiliate links.

Hims and Noom are frequently compared, yet they started from opposite ends of weight management. Hims grew up as a prescriber-first telehealth service; Noom grew up as a behavior-change app that later added a medication path. Reading the two side by side is less about which is better and more about what each was designed to do. This overview separates the coaching layer from the prescribing layer and flags the genetic input both skip.

What Hims brings as a prescriber

Hims, under Hims & Hers Health, centers on the clinical transaction: intake, provider review, and a prescription for an FDA-approved branded GLP-1 or for compounded semaglutide or tirzepatide from a licensed pharmacy. The subscription bundles that clinical workflow. See the Hims weight-loss page for the current shape of the program.

What Noom brings as a behavior-change app

Noom (Noom, Inc.) is rooted in psychology-based coaching, food logging, and habit change, with a medication add-on layered on top for eligible members. The lived experience leans on daily app engagement rather than the prescription alone. Program tiers and medication options move over time; the Noom Med page carries the current details.

Medication access: prescription versus add-on

The practical fork is how central the drug is. On a prescriber-first platform the medication is the product; on a behavior-first platform the medication supplements the coaching. Someone who wants structured habit support may value the app scaffolding, while someone focused mainly on the prescription may find a leaner clinical service more direct.

The clinical evidence sits with the compound

No app or subscription changes the underlying pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide have been studied in programs such as STEP (NEJM 2021), SURMOUNT (NEJM 2022), and SURMOUNT-OSA (NEJM 2024). Results vary by compound, dose, and person; the platform delivering the molecule does not alter the molecule.

Matching the program to your goal

The honest way to choose is to name your goal first. If you want daily structure, food logging, and psychology-based coaching to build lasting habits, a behavior-first platform is designed for that. If your main need is efficient access to a prescription with clinical oversight and titration support, a prescriber-first service is the more direct path. Many people benefit from both layers, but the two brands weight them differently, and knowing which layer you actually want prevents paying for features you will not use.

The upstream genetics both leave out

Coaching streaks and prescriptions both sit downstream of biology neither brand reads. Variants in MC4R, a melanocortin receptor central to satiety and energy balance, together with FTO and TCF7L2, shape the metabolic baseline any GLP-1 protocol acts on. The PlexusDx Precision Peptide Genetic Test examines 14 pathways, 49 peptides, 150+ genetic insights, describing that baseline without predicting your response to any particular drug.

Where a genetic-first approach fits

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, including Semaglutide Injection ($189/month), Tirzepatide Injection ($289/month), and a microdose option at $129/month flat. Running the Precision Peptide Genetic Test first, priced at $298 or $99 for program members, turns a metabolic decision into an informed one.

Not affiliated: PlexusDx has no commercial relationship with Hims, Noom, or the other brands mentioned here.

Keep reading on PlexusDx: GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1, GLP-1 What Is.

Editorial note: this piece is for education. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is unaffiliated with the reviewed brands. The Precision Peptide Genetic Test reports genetic influence on peptide pathways and does not forecast medication response. Consult a qualified provider before beginning a protocol.

Frequently Asked Questions

Is Noom mainly an app or a medication service?

Noom began as a psychology-based coaching app and later added a medication path for eligible members, so it functions as both. If your priority is structured behavior change, the app layer matters; if it is primarily the prescription, evaluate how central the medication is within the tier you are considering.

Does Hims include coaching like Noom?

Hims is built first around clinical evaluation and prescribing rather than a daily coaching curriculum. Support features exist, but the emphasis differs from a behavior-change platform. If sustained habit coaching is what you want, compare the specific support each brand currently advertises on its own site.

Do both offer the same GLP-1 medications?

Both can work within the GLP-1 class and may provide semaglutide or tirzepatide subject to eligibility and availability. The pharmacology is shared across legitimate programs; the real differences are the surrounding model, coaching depth, and whether the drug is dispensed as a branded or compounded product.

Can genetic testing improve results on either program?

Genetic testing does not boost a drug, but it adds context. The Precision Peptide Genetic Test maps variants such as MC4R and FTO that shape appetite and energy balance, giving you and your provider a fuller picture before a protocol begins, regardless of which platform ultimately supports you.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education